- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03291275
Survival Outcomes of Uterine Malignancies in Chinese Population
February 7, 2018 updated by: Lei Li
This study aims to determine survival outcomes (overall survival and progression-free survival) of primary uterine malignancies in China and relevant risk factors in a prospective cohort study.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Anticipated)
10000
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Lei Li, MD
- Phone Number: +86 13911988831
- Email: lileigh@163.com
Study Locations
-
-
China/Beiing
-
Beijing, China/Beiing, China, 100000
- Recruiting
- Lei Li
-
Contact:
- Lei L Li, MD
- Phone Number: +86 13911988831
- Email: lileigh@163.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Sampling Method
Non-Probability Sample
Study Population
All patients with definite diagnosis of uterine malignancies in China.
Description
Inclusion Criteria:
- Primary uterine malignancies.
Exclusion Criteria:
- Metastatic malignancies to uterine corpus
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival
Time Frame: 5 years
|
Survival duration from diagnosis to death
|
5 years
|
Progression-free survival
Time Frame: 5 years
|
Survival duration from last treatment after remission to recurrence
|
5 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Lei Li, MD, Peking Union Medical College Hospital
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 1, 2017
Primary Completion (Anticipated)
September 1, 2022
Study Completion (Anticipated)
September 1, 2023
Study Registration Dates
First Submitted
September 20, 2017
First Submitted That Met QC Criteria
September 20, 2017
First Posted (Actual)
September 25, 2017
Study Record Updates
Last Update Posted (Actual)
February 8, 2018
Last Update Submitted That Met QC Criteria
February 7, 2018
Last Verified
February 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SOUM-1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Endometrial Neoplasms
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnAtypical Endometrial Hyperplasia | Recurrent Endometrial Carcinoma | Endometrial Adenocarcinoma | Stage IA Endometrial Carcinoma | Stage IB Endometrial Carcinoma | Stage II Endometrial Carcinoma | Stage IIIA Endometrial Carcinoma | Stage IIIB Endometrial Carcinoma | Stage IIIC Endometrial Carcinoma | Stage... and other conditions
-
Case Comprehensive Cancer CenterTerminatedStage IV Endometrial Carcinoma | Stage III Endometrial Carcinoma | Stage II Endometrial Carcinoma | Stage I Endometrial CarcinomaUnited States
-
Sohag UniversityNot yet recruitingEndometrial Cancer and Endometrial HyperplasiaEgypt
-
CHU de ReimsUnknownEndometrial Hyperplasia and Endometrial CancersFrance
-
National Cancer Institute (NCI)CompletedRecurrent Endometrial Carcinoma | Endometrial Adenocarcinoma | Endometrial Clear Cell Carcinoma | Endometrial Papillary Serous Carcinoma | Stage IIIA Endometrial Carcinoma | Stage IIIB Endometrial Carcinoma | Stage IIIC Endometrial Carcinoma | Stage IVA Endometrial Carcinoma | Stage IVB Endometrial... and other conditionsCanada
-
Assistance Publique - Hôpitaux de ParisUniversité Montpellier; Ecole d'econmie de Paris (PSE)-Hospinnomics; Université...CompletedEndometrial Cancer Stage I | Endometrial Cancer Stage IIFrance
-
Peking University People's HospitalPeking University; Beihang UniversityRecruitingAtypical Endometrial Hyperplasia | Endometrial Carcinoma Stage IChina
-
Washington University School of MedicineMerck Sharp & Dohme LLCCompletedEndometrial Cancer | Endometrial Carcinoma | Neoplasms, EndometrialUnited States
-
Radboud University Medical CenterMaastricht University Medical Center; Erasmus Medical Center; Catharina Ziekenhuis... and other collaboratorsRecruitingEndometrial Cancer Recurrent | Endometrial Cancer Stage III | Endometrial Cancer Stage IVNetherlands
-
Imperial College LondonRecruitingEndometrial Hyperplasia | Endometrial Neoplasms | Endometrial Cancer | Endometrial PolypUnited Kingdom
Clinical Trials on Follow-up for death and recurrence
-
Lei LiUnknown
-
Lei LiUnknownUterine Cervical Neoplasms | SurvivalChina
-
St. James's Hospital, IrelandKarolinska Institutet; St Mary's Hospital, Paddington, LondonCompletedEsophageal Cancer | Chemoradiation | Chemotherapy | Surgery | Metastatic Cancer | Radiation | Recurrent Esophageal CancerSweden, Ireland, United Kingdom
-
Changi General HospitalCompleted
-
Universidad de la SabanaNot yet recruitingCovid19 | SARS-CoV InfectionColombia
-
Ontario Clinical Oncology Group (OCOG)Canadian Breast Cancer InitiativeCompleted
-
Dokuz Eylul UniversityCompletedInfantile Colic | Self Efficacy | Jaundice, Neonatal | Breastfeeding, ExclusiveTurkey
-
University Hospitals Bristol and Weston NHS Foundation...CompletedPost Traumatic Stress DisorderUnited Kingdom
-
Harvard Medical School (HMS and HSDM)Completed
-
University of IcelandMemorial Sloan Kettering Cancer Center; Landspitali University Hospital; deCODE... and other collaboratorsActive, not recruitingMonoclonal Gammopathy of Undetermined SignificanceIceland